Leede Financial Comments on TSE:ONC FY2024 Earnings

Oncolytics Biotech Inc. (TSE:ONC) – Equities researchers at Leede Financial issued their FY2024 earnings per share (EPS) estimates for shares of Oncolytics Biotech in a note issued to investors on Wednesday, November 13th. Leede Financial analyst D. Loe expects that the company will earn ($0.34) per share for the year. The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.41) per share. Leede Financial also issued estimates for Oncolytics Biotech’s FY2025 earnings at ($0.41) EPS, FY2026 earnings at ($0.43) EPS, FY2027 earnings at ($0.33) EPS and FY2028 earnings at ($0.05) EPS.

Separately, Raymond James raised shares of Oncolytics Biotech to a “moderate buy” rating in a report on Thursday, November 14th.

Oncolytics Biotech Price Performance

Shares of ONC opened at C$1.48 on Monday. Oncolytics Biotech has a 12 month low of C$1.15 and a 12 month high of C$2.32. The company has a debt-to-equity ratio of 6.09, a current ratio of 4.99 and a quick ratio of 8.86. The stock has a fifty day moving average price of C$1.50 and a 200 day moving average price of C$1.45. The company has a market cap of C$113.75 million, a P/E ratio of -3.68 and a beta of 1.35.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.